Full article: Acute kidney injury in patients receiving high-dose etoposide phosphate as
conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be …

… Carmustine shortage has led to an increase use of alternative … The onset of acute kidney
failure following BeEAM regimens … Etoposide was administered twice a day in 2 hours infusion …

… pneumonia syndrome following stem cell transplantation or … creatinine to acute renal failure
requiring dialysis. Therefore, … of carboplatin for autologous stem cell transplant conditioning …

… Such defined AKI occurs in 12–21% of patients undergoing autologous HCT (autoHCT) [4],
[… of clinical workup in acute kidney injury (AKI) after hematopoietic cell transplantation (HCT). …

… , BEAM (carmustine 300 mg/m 2 IV on day −6, etoposide 100 … and 4% of pre-renal acute
kidney injury. This dose was chosen … and autologous bone marrow transplantation after failure of …

… , either by replacing carmustine in the BEAM regimen thereby … /m 2 /day on days −7 and −6,
etoposide 200 mg/m 2 /day and … We identified acute kidney injury (rAKI) in 41.8% of MM and …

… The combination of carmustine, etoposide, cytarabine, and … Briefly, acute kidney failure
(ARF) was defined according to … the normal value at 10 (6 to 21) days after graft infusion. Two …

… , which occurs in 10% to 70% of patients following treatment … of acute kidney injury (AKI)
in autologous stem cell transplant … had myeloma and dialysis-dependent renal failure. All of …

… and mortality after ASCT, we assessed the 100-day morbidity defined as orotracheal intubation
(OTI), dialysis or … disorders like carmustine, cyclophosphamide, etoposide or carmustine, …

… instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) …
was acute renal failure, which developed in four patients (6.7%) shortly after bendamustine …